Summary
12.03 0.32(2.69%)05/16/2024
Sage Therapeutics Inc (SAGE)
Sage Therapeutics Inc (SAGE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.23 | -6.90 | -21.97 | -45.89 | -33.98 | -74.82 | -92.26 | -56.94 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 12.96 | |
| Open | 13.22 | |
| High | 13.24 | |
| Low | 12.63 | |
| Volume | 668,100 | |
| Change | -0.30 | |
| Change % | -2.23 | |
| Avg Volume (20 Days) | 1,100,767 | |
| Volume/Avg Volume (20 Days) Ratio | 0.61 | |
| 52 Week Range | 10.92 - 59.98 | |
| Price vs 52 Week High | -78.39% | |
| Price vs 52 Week Low | 18.68% | |
| Range | -1.97 | |
| Gap Up/Down | -1.09 | |
Fundamentals | ||
| Market Capitalization (Mln) | 707 | |
| EBIDTA | -507,262,016 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.7400 | |
| WallStreet Target Price | 21.88 | |
| Book Value | 11.7280 | |
| Earnings Per Share | -8.3900 | |
| EPS Estimate Current Quarter | -1.6500 | |
| EPS Estimate Next Quarter | -1.6400 | |
| EPS Estimate Current Year | -6.5900 | |
| EPS Estimate Next Year | -5.1400 | |
| Diluted EPS (TTM) | -8.3900 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -14.8918 | |
| Return on asset (TTM) | -0.3198 | |
| Return on equity (TTM) | -0.5472 | |
| Revenue TTM | 91,063,000 | |
| Revenue per share TTM | 1.5190 | |
| Quarterly Revenue Growth (YOY) | 1.3990 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -319,290,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.1622 | |
| Revenue Enterprise Value | 2.0962 | |
| EBITDA Enterprise Value | -0.3325 | |
| Shares | ||
| Shares Outstanding | 60,182,000 | |
| Shares Float | 47,797,171 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.15 | |
| Insider (%) | 12.47 | |
| Institutions (%) | 94.60 | |
05/16 21:01 EST - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
05/16 12:45 EST - accesswire.com
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
05/15 20:00 EST - accesswire.com
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
05/10 07:20 EST - accesswire.com
Investors who lost money on Sage Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - SAGE
NEW YORK, NY / ACCESSWIRE / May 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
Investors who lost money on Sage Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - SAGE
NEW YORK, NY / ACCESSWIRE / May 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
05/08 20:30 EST - accesswire.com
SAGE ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sage Therapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / May 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
SAGE ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sage Therapeutics, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / May 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
05/08 07:30 EST - accesswire.com
SAGE ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Sage Therapeutics, Inc. investment
NEW YORK, NY / ACCESSWIRE / May 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
SAGE ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Sage Therapeutics, Inc. investment
NEW YORK, NY / ACCESSWIRE / May 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
05/07 06:30 EST - businesswire.com
Sage Therapeutics to Participate in Upcoming May Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor conferences in May: 2024 RBCCM Global Healthcare Conference (New York, NY): fireside chat on Tuesday, May 14, 2024 at 11:30 a.m. ET. BofA Securities 2024 Health Care Conference (Las Vegas, NV): fireside chat on Wednesday, May 15, 2024 at 10:00 a.m. PT.
Sage Therapeutics to Participate in Upcoming May Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor conferences in May: 2024 RBCCM Global Healthcare Conference (New York, NY): fireside chat on Tuesday, May 14, 2024 at 11:30 a.m. ET. BofA Securities 2024 Health Care Conference (Las Vegas, NV): fireside chat on Wednesday, May 15, 2024 at 10:00 a.m. PT.
05/06 19:30 EST - accesswire.com
Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – SAGE
NEW YORK, NY / ACCESSWIRE / May 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – SAGE
NEW YORK, NY / ACCESSWIRE / May 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
05/06 18:37 EST - prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE
NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
05/06 07:30 EST - accesswire.com
Sage Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sage Therapeutics (SAGE)
NEW YORK, NY / ACCESSWIRE / May 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
Sage Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sage Therapeutics (SAGE)
NEW YORK, NY / ACCESSWIRE / May 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
05/04 21:00 EST - accesswire.com
SAGE ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Sage Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
SAGE ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Sage Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
05/04 21:00 EST - accesswire.com
Sage Therapeutics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SAGE
NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
Sage Therapeutics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SAGE
NEW YORK, NY / ACCESSWIRE / May 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
05/02 16:45 EST - accesswire.com
ATTENTION Sage Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
ATTENTION Sage Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
05/02 16:45 EST - accesswire.com
Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SAGE
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SAGE
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
05/02 10:00 EST - accesswire.com
An Investigation Has Commenced on Behalf of Sage Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SAGE Losses.
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
An Investigation Has Commenced on Behalf of Sage Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SAGE Losses.
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sage Therapeutics, Inc. ("Sage Therapeutics") (NASDAQ:SAGE) concerning possible violations of federal securities laws. Before the market opened on April 17, 2024, Sage issued a press release "announc[ing].
04/26 12:31 EST - zacks.com
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
04/25 14:17 EST - seekingalpha.com
Sage Therapeutics, Inc. (SAGE) Q1 2024 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q1 2024 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Ashley Kaplowitz - Vice President-Investor Relations & Capital Markets Barry Greene - Chief Executive Officer & Member-Board of Directors Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - JPMorgan Ritu Baral - TD Cowen Laura Chico - Wedbush Securities Paul Matteis - Stifel Jay Olson - Oppenheimer Ami Fadia - Needham Brian Abrahams - RBC Capital Markets George Farmer - Scotiabank Sumant Kulkarni - Canaccord Yatin Suneja - Guggenheim Douglas Tsao - HC Wainwright Operator Good morning, and welcome to Sage Therapeutics First Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Sage Therapeutics, Inc. (SAGE) Q1 2024 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q1 2024 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Ashley Kaplowitz - Vice President-Investor Relations & Capital Markets Barry Greene - Chief Executive Officer & Member-Board of Directors Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - JPMorgan Ritu Baral - TD Cowen Laura Chico - Wedbush Securities Paul Matteis - Stifel Jay Olson - Oppenheimer Ami Fadia - Needham Brian Abrahams - RBC Capital Markets George Farmer - Scotiabank Sumant Kulkarni - Canaccord Yatin Suneja - Guggenheim Douglas Tsao - HC Wainwright Operator Good morning, and welcome to Sage Therapeutics First Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.